Roberto AJ, Pires RNC, Leme AF, Bueno OG, Roberto AC

Idioma: Portugués
Referencias bibliográficas: 7
Paginas: 199-201
Archivo PDF: 382.56 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Romiti R. Compêndio de psoríase. Editora Elsevier, Rio de Janeiro, 2010, p. 252.

2. Targa FC, Ferreira CT, Fernandes EI, Themis RS. Psoríase pustulosa associada à doença de Crohn: relato de caso. An Bras Dermatol, Rio de Janeiro. 2000; 75 (1): 57-64.

3. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor TNF- monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000; 42: 829-830.

4. Arruda L, Ypiranga S, Aires MG. Tratamento sistêmico da psoríase - Parte II: Imunomoduladores biológicos. An Bras Dermatol [online]. 2004; 79 (4): 393-408.

5. Rocha MAP, Gemio TM, Scanavini NA, Viera SFE, Correa ORL, Thierry R et al. Tratamento da doença de Crohn com infliximabe: primeira opção? ABCD, Arq Bras Cir Dig. 2009; 22 (2): 101-104.

6. Kawashima K, Ishihara S, Yamamoto A, Ohno Y, Fukuda K, Onishi K, Kinoshita Y. Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn’s disease. Inflamm Bowel Dis. 2012 Apr 16. doi: 10.1002/ibd.22922.

7. Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther. 2012; 35 (12): 1397-1407.